A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer

Abramson Cancer Center at Penn Medicine

Status: Completed

Conditions: Lung Cancer

Treatments: Other: Blood and Urine Collection

Study type: Observational

Funder types: Other

Identifiers

NCT03047616

27516

Details and patient eligibility

About

Several immune checkpoint inhibitors targeting the PD-1 pathway have been developed with clinical trials showing an approximately 20% durable response in unselected patients with advanced non-small cell lung cancer (NSCLC). At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 tumor responsiveness. The goal of this study is to broadly discover and evaluate the utility of blood based biomarkers for use in measuring and predicting response to immunotherapy in patients with lung cancer.

Enrollment: 88 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced Metastatic NSCLC
• Scheduled to initiate an immune checkpoint inhibitor
• Age >= 18 years
• Able to provide informed consent

Exclusion criteria

• Other, unrelated, concomitant active, invasive malignancy

Trial design